Vaccines
4 January 2023
Evaxion receives approval from FDA to proceed with the clinical Phase 2b study for EVX-0122 December 2022
BioNTech Starts Phase 1 Clinical Trial for Prophylactic Herpes Simplex Virus-2 Vaccine Candidate BNT16321 December 2022
VidPrevtyn Beta COVID-19 booster vaccine, developed by Sanofi and GSK, approved for use in Great Britain20 December 2022
BioLineRx Announces Results from Phase 1/2a Study of Investigational Anti-Tumor Vaccine AGI-134 in Metastatic Solid Tumors15 December 2022
Everest Medicines Announces New mRNA Rabies Vaccine Program and Achievement of Preclinical Proof-of-Concept Milestone12 December 2022
Amphera Announces Clinical Updates of MesoPher Cell Therapy9 December 2022
PDC*line Pharma Presents First Immunological Results From Phase I/II Trial With PDC*lung01 at ESMO-IO 20228 December 2022
Takeda’s QDENGA (Dengue Tetravalent Vaccine [Live, Attenuated]) Approved for Use in European Union5 December 2022
Valneva Reports Positive 12-Month Antibody Persistence Data for Single-Shot Chikungunya Vaccine Candidate1 December 2022
AC Immune’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 Selected for Further Development30 November 2022
Intravacc launches phase I clinical trial of Avacc 10®, an intranasal subunit booster vaccine for SARS-CoV-223 November 2022
Takeda’s Biologics License Application (BLA) for Dengue Vaccine Candidate (TAK-003) Granted Priority Review by U.S. Food and Drug Administration21 November 2022
Immorna Receives IND Clearance to Conduct a Phase 1/2 Study of JCXH-221, a Broadly Protective mRNA-Based COVID-19 Vaccine18 November 2022
INOVIO Provides an Update on Lassa Fever and MERS Programs18 November 2022
Northwest Biotherapeutics Reports Positive Top-Line Results From Phase 3 Trial of DCVax®-L for Glioblastoma17 November 2022
Escient Pharmaceuticals Initiates Phase 2 PACIFIC Study Evaluating EP547, An Oral MRGPRX4 Antagonist, in Subjects with Cholestatic Pruritus17 November 2022
Evaxion announces promising results from Phase 1/2a clinical trial of personalized DNA cancer immunotherapy EVX-0217 November 2022
Curevo Vaccine Announces $26 Million Series A1 Financing to Support Clinical Development of Next-Generation Subunit Vaccines15 November 2022
Daiichi Sankyo Announces Results of Booster Vaccination Trial of Its mRNA COVID-19 Vaccine (DS-5670) in JapanNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports